Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Domain Adaptation leverages lymphoma EHRs to better predict infection risk from treatment-related immune suppression in CLL, boosting Matthews correlation coefficient.

Real-world data show liso-cel drives high responses in relapsed/refractory CLL, with an 85% ORR, a 44% CR rate, and manageable safety.

A new review highlights the potential to develop ways to better anticipate and treat Richter transformation in patients with chronic lymphocytic leukemia.

Mitochondrial DNA heteroplasmy is independently associated with an increased risk of CLL, suggesting potential as a novel biomarker for early risk identification.

Bruton tyrosine kinase–based therapies show promising but variable efficacy in Richter transformation, current data suggest.

The FDA approved acalabrutinib and venetoclax, a fixed‑duration all‑oral CLL/SLL first‑line combo, based on phase 3 AMPLIFY trial data.

Data suggest the benefits of zanubrutinib versus acalabrutinib in R/R chronic lymphocytic leukemia were even more pronounced in high-risk cases.

Margaret Krackeler, MD, of Kaiser Permanente Northern California, shares lessons on implementing evidence-based formulary changes for patients with CLL.

Real-world ONCare data show acalabrutinib lowers new-onset HTN, CV events, and discontinuations vs ibrutinib in R/R CLL/SLL.

This new study reveals venetoclax and rituximab effectively treat chronic lymphocytic leukemia, showing high response rates and prolonged progression-free survival.

A review article focused on first-line treatment of chronic lymphocytic leukemia highlights the importance of shared decision-making.

IGHV-unmutated CLL comprises 2 distinct epigenetic subtypes with different B-cell maturation signatures and genetic alterations, a study found.

Richter transformation with CNS involvement in CLL presents a poor prognosis, highlighting the need for tailored treatment strategies and further research.

In an interview during ASH 2025, Ontada's Ira Zackon, MD explores the role of BTK inhibitors in chronic lymphocytic leukemia treatment, highlighting real-world challenges and emerging therapy strategies.

ASH 2025 reveals groundbreaking trial data on fixed-duration therapies for chronic lymphocytic leukemia, non-Hodgkin lymphoma, and multiple myeloma, enhancing patient outcomes and reducing costs.

This year’s most-read articles on CLL highlighted research and insights on personalized therapy, long-term remission, and next-generation cell treatments.

Sequential BTK and BCL2 inhibitors yield high initial response rates, but durability remains a challenge in the real-world setting for CLL.

Real-world evidence highlights the effectiveness of lisocabtagene maraleucel in treating relapsed or refractory chronic lymphocytic leukemia (R/R CLL).

With a follow-up of up to 6 years, the median progression-free survival for long-term extension participants was 52.5 months.

The study suggests that adding a Bruton tyrosine kinase inhibitor (BTKi) to frontline chemoimmunotherapy in Richter transformation improved complete response rates and progression-free survival compared with chemoimmunotherapy alone, though overall survival benefits remained unclear.

There is no cure for chronic lymphocytic leukemia, but an array of new therapeutic strategies are improving outcomes for patients.

Pirtobrutinib significantly improved progression-free survival in treatment-naïve CLL compared with bendamustine plus rituximab.

Adequate CD19-positive cell content is required to reliably identify both dominant and subclonal TP53 mutations.

Pirtobrutinib is now fully approved for CLL/SLL in those previously treated with Bruton tyrosine kinase inhibitors.